Chloride dysregulation: the next target for chronic pain therapeutics
- 1CERVO Brain Research Centre, Department of Psychiatry & Neuroscience, Department of Anesthesiology & Intensive Care, Université Laval, Quebec, QC, Canada
Abstract
Chronic pain affects a substantial fraction of the population, yet pharmacological management remains deeply inadequate. This failure likely reflects the focus on developing analgesics suppressing normal nociceptive signalling rather than correcting the pathological substrates distinguishing chronic from acute pain. Here we review how the identification of injury-induced downregulation of the potassium-chloride cotransporter KCC2 in spinal dorsal horn neurons represents a landmark. It first provided a mechanistic, long-term substrate for spinal inhibitory failure. This form of disinhibition had the potential to explain several cardinal symptoms of neuropathic pain; not just hyperalgesia, through spinal hyperexcitability, and tactile allodynia, through cross-talk between sensory modalities, but also spontaneous pain, through enabling spontaneous bursts of activity in spinal nociceptive output to emerge. A second landmark is that chloride dysregulation as a substrate of disinhibition yields non-linear, non-intuitive predictions of neural circuit behaviours that shed light on several features of chronic pain and its therapeutic challenges. One is paradoxical pro-excitatory actions of tapping into normally endogenous inhibitory neurotransmission, potentially explaining failures of benzodiazepines analgesia and of conditional pain modulation. Others include degradation of sensory processing, possibly explaining diffuse pain, and leaky plasticity, predisposing to catastrophic sensitization. In turn, mechanisms regulating KCC2 itself emerge as substrates of chronification, as well as substrates of opioid-induced maladaptive paradoxical hyperalgesia. Finally, divergent yet convergent signaling cascades underlying KCC2-downregulation reveal a form of pathway degeneracy across sexes with lessons for therapeutics. All-in-all, these findings position KCC2 as a key novel target, not just for analgesia, but also for disease modification.
Related
- Next-generation therapeutics for glioblastoma: Challenges and future directions
- Clostridioides difficile infections and beyond: molecular epidemiology, One Health transmission chains, under-surveilled regions, and the next generation of diagnostics, therapeutics, and vaccines
- WHO Target Product Profiles for Dengue Therapeutics: An Interdisciplinary Analysis of Ethical, Regulatory, and Implementation Considerations
- The next frontier of peptide therapeutics: from targeted conjugates (PDC/ODC) to AI-driven safety-by-design
- Organoid-Guided Synthetic Micropeptide Therapeutics to Target Ovarian Cancer Stem Cells
BibTeX
@article{koninck2026chloride,
title = {{Chloride dysregulation: the next target for chronic pain therapeutics}},
author = {Yves De Koninck},
journal = {Pain},
year = {2026},
month = oct,
doi = {10.1097/j.pain.0000000000004110},
url = {https://europepmc.org/article/PMC/PMC13714770},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Chloride dysregulation: the next target for chronic pain therapeutics
AU - Yves De Koninck
PY - 2026
DA - 2026/10/31
JO - Pain
DO - 10.1097/j.pain.0000000000004110
UR - https://europepmc.org/article/PMC/PMC13714770
AB - Chronic pain affects a substantial fraction of the population, yet pharmacological management remains deeply inadequate. This failure likely reflects the focus on developing analgesics suppressing normal nociceptive signalling rather than correcting the pathological substrates distinguishing chronic from acute pain. Here we review how the identification of injury-induced downregulation of the potassium-chloride cotransporter KCC2 in spinal dorsal horn neurons represents a landmark. It first provided a mechanistic, long-term substrate for spinal inhibitory failure. This form of disinhibition had the potential to explain several cardinal symptoms of neuropathic pain; not just hyperalgesia, through spinal hyperexcitability, and tactile allodynia, through cross-talk between sensory modalities, but also spontaneous pain, through enabling spontaneous bursts of activity in spinal nociceptive output to emerge. A second landmark is that chloride dysregulation as a substrate of disinhibition yields non-linear, non-intuitive predictions of neural circuit behaviours that shed light on several features of chronic pain and its therapeutic challenges. One is paradoxical pro-excitatory actions of tapping into normally endogenous inhibitory neurotransmission, potentially explaining failures of benzodiazepines analgesia and of conditional pain modulation. Others include degradation of sensory processing, possibly explaining diffuse pain, and leaky plasticity, predisposing to catastrophic sensitization. In turn, mechanisms regulating KCC2 itself emerge as substrates of chronification, as well as substrates of opioid-induced maladaptive paradoxical hyperalgesia. Finally, divergent yet convergent signaling cascades underlying KCC2-downregulation reveal a form of pathway degeneracy across sexes with lessons for therapeutics. All-in-all, these findings position KCC2 as a key novel target, not just for analgesia, but also for disease modification.
SN - 0304-3959
SN - 1872-6623
ER -